In patients with mantle cell lymphoma in the relapsed or refractory setting, a combination of Venetoclax plus Ibrutinib shows efficacy, which was associated with expansion in CCR7-CD45RA+ CD8+ and CD4+ TEMRA with improved function 60. The gene discussed is CD8A; the disease is mantle cell lymphoma.